Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to use Exenatide long-acting release (LAR) [Bydureon] to minimize
vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI)
and to accelerate stent endothelialisation.